THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was ...

THOUSAND OAKS, Calif. and BRUSSELS, Oct. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for ...

Evenity is prescribed as a monthly subcutaneous injection to treat osteoporosis after menopause. Each dose consists of 2 prefilled syringes administered by a healthcare professional. Typical Evenity ...

(Reuters) - Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug ...

THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 ...

Evenity’s dosage is 210 milligrams per month for a total of 12 months. Each dose consists of two injections given by a healthcare professional. You’ll take calcium and vitamin D supplements with ...

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab) to ...

The #FierceMadness drug name tournament concludes with an Evenity victory over Brukinsa. (Carly Helfand) The #FierceMadness drug name champion is Evenity. The Amgen osteoporosis drug triumphed over ...

Evenity's FDA approval comes with a boxed warning that alerts of its cardiovascular risks. (Amgen) () Amgen and UCB’s osteoporosis drug Evenity has finally won over the FDA, thanks to a pared-back ...

The approval of EVENITY in the U.S. helps address an unmet need by providing another option for postmenopausal women at high risk for fracture who need to build bone rapidly within 12 months and to ...